N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis.
[en] A series of chroman derivatives previously reported as potassium channel openers, as well as some newly synthesized simplified structures, were examined for their in vitro effects on the growth of three human high-grade glioma cell lines: U373, T98G, and Hs683. Significant in vitro growth inhibitory activity was observed with 2,2-dimethylchroman-type nitro-substituted phenylthioureas, such as compounds 4o and 4p. Interestingly, most tested phenylureas were found to be slightly less active, but more cell selective (normal versus tumor glial cells, such as 3d, 3e, and 3g), thus less toxic, than the corresponding phenylthioureas. No significant differences were observed in terms of chroman-derivative-induced growth inhibitory effects between glioma cells sensitive to pro-apoptotic stimuli (Hs683 glioma cells) and glioma cells associated with various levels of resistance to pro-apoptotic stimuli (U373 and T98G glioma cells), a feature that suggests non-apoptotic-mediated growth inhibition. Flow cytometry analyses confirmed the absence of pro-apoptotic effects for phenylthioureas and phenylureas when analyzed in U373 glioma cells and demonstrated U373 cell cycle arrest in the G0/G1 phase. Computer-assisted phase-contrast videomicroscopy revealed that 3d and 3g displayed cytostatic effects, while 3e displayed cytotoxic ones. As a result, this work identified phenylurea-type 2,2-dimethylchromans as a new class of antitumor agents to be further explored for an innovative therapeutic approach for high-grade glioma and/or for a possible new mechanism of action.
Disciplines :
Neurosciences & behavior
Author, co-author :
Goffin, Eric ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Lamoral-Theys, Delphine
Tajeddine, Nicolas
De Tullio, Pascal ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Mondin, Ludivine
Lefranc, Florence
Gailly, Philippe
ROGISTER, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Neurologie Sart Tilman
Kiss, Robert
Pirotte, Bernard ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Language :
English
Title :
N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: screening, synthesis of simplified derivatives, and structure-activity relationship analysis.
Publication date :
2012
Journal title :
European Journal of Medicinal Chemistry
ISSN :
0223-5234
eISSN :
1768-3254
Publisher :
Elsevier, Netherlands
Volume :
54
Pages :
834-44
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2012 Elsevier Masson SAS. All rights reserved.
A. Giese, R. Bjerkvig, M.E. Berens, and M. Westphal Cost of migration: invasion of malignant gliomas and implications for treatment J. Clin. Oncol. 21 2003 1624 1636 (Pubitemid 46594118)
F. Lefranc, J. Brotchi, and R. Kiss Possible future issues in the treatment of glioblastomas, with a special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis J. Clin. Oncol. 23 2005 2411 2422 (Pubitemid 46218735)
F. Lefranc, N. Sadeghi, I. Camby, T. Metens, O. Dewitte, and R. Kiss Present and potential future issues in glioblastoma treatment Expert Rev. Anticancer Ther. 6 2006 719 732 (Pubitemid 44192888)
F. Lefranc, V. Facchini, and R. Kiss Pro-autophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas Oncologist 12 2007 1395 1403
R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J.B. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, and R.O. Mirimanoff Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
T. Kanzawa, I.M. Germano, T. Komata, H. Ito, Y. Kondo, and S. Kondo Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells Cell Death Differ. 11 2004 448 457 (Pubitemid 38489422)
W.P. Roos, L.F. Batista, S.C. Naumann, W. Wick, M. Weller, C.F. Menck, and B. Kaina Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine Oncogene 26 2007 186 197 (Pubitemid 46095730)
V. Mathieu, N. De Neve, M. Le Mercier, J. Dewelle, J.F. Gaussin, M. Dehoux, R. Kiss, and F. Lefranc Combining bevacizumab with temozolomide increases the anti-tumor efficacy of temozolomide in human glioblastoma orthotopic xenograft model Neoplasia 10 2008 1383 1392
H. Sontheimer Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage Trends Neurosci. 26 2003 543 549 (Pubitemid 37176909)
H. Sontheimer Ion channels and amino acid transporters support the growth and invasion of primary brain tumors Mol. Neurobiol. 29 2004 61 71 (Pubitemid 39118079)
H. Sontheimer An unexpected role for ion channels in brain tumor metastasis Exp. Biol. Med. (Maywood) 233 2008 779 791
F. Lefranc, and R. Kiss The sodium pump alpha-1 subunit as a potential target to combat apoptosis-resistant glioblastomas Neoplasia 10 2008 198 206 (Pubitemid 351328589)
F. Lefranc, T. Mijatovic, Y. Kondo, S. Sauvage, I. Roland, D. Krstic, V. Vasic, P. Gailly, S. Kondo, G. Blanco, and R. Kiss Targeting the alpha-1 subunit of the sodium pump (the Na+/K+-ATPase) to combat glioblastoma cells Neurosurgery 62 2008 211 222
V.A. Cuddapah, and H. Sontheimer Ion channels and the control of cancer cell migration Am. J. Physiol. Cell Physiol. 301 2011 C541 549
S. Sebille, P. de Tullio, B. Becker, M.-H. Antoine, S. Boverie, B. Pirotte, and P. Lebrun 4,6-Disubstituted 2,2-dimethylchromans structurally related to the KATP channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone J. Med. Chem. 48 2005 614 621 (Pubitemid 40139803)
S. Sebille, D. Gall, P. de Tullio, X. Florence, P. Lebrun, and B. Pirotte Design, synthesis and pharmacological evaluation of R/S-3,4-dihydro-2,2- dimethyl-6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: towards tissue-selective pancreatic B-cells KATP channel openers structurally related to (±)-cromakalim J. Med. Chem. 49 2006 4690 4697 (Pubitemid 44162696)
S. Sebille, P. de Tullio, X. Florence, B. Becker, M.-H. Antoine, C. Michaux, J. Wouters, B. Pirotte, and P. Lebrun New R/S-3,4-Dihydro-2,2-dimethyl- 6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (±)-cromakalim as tissue-selective pancreatic beta-cell KATP channel openers Bioorg. Med. Chem. 16 2008 5704 5719 (Pubitemid 351699279)
X. Florence, S. Sebille, P. de Tullio, P. Lebrun, and B. Pirotte New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as KATP channel openers: modulation of the 4-position Bioorg. Med. Chem. 17 2009 7723 7731
P. de Tullio, S. Boverie, B. Becker, M.-H. Antoine, Q.A. Nguyen, P. Francotte, S. Counerotte, S. Sebille, B. Pirotte, and P. Lebrun 3-Alkylamino-4H-1,2,4-benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity J. Med. Chem. 48 2005 4990 5000 (Pubitemid 41033139)
P. de Tullio, B. Becker, S. Boverie, M. Dabrowski, P. Wahl, F. Somers, S. Sebille, R. Ouedraogo, J.B. Hansen, P. Lebrun, and B. Pirotte Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides J. Med. Chem. 46 2003 3342 3353 (Pubitemid 36842419)
H. Hibino, A. Inanobe, K. Furutani, S. Murakami, I. Findlay, and Y. Kurachi Inwardly rectifying potassium channels: their structure, function, and physiological roles Physiol. Rev. 90 2010 291 366
M.L. Olsen, and H. Sontheimer Mislocalization of Kir channels in malignant glia Glia 46 2004 63 73 (Pubitemid 38461724)
G. Tan, S.Q. Sun, and D.L. Yuan Expression of Kir 4.1 in human astrocytic tumors: correlation with pathologic grade Biochem. Biophys. Res. Commun. 367 2008 743 747
L.M. Simar, K.T. Kahle, and V. Gerzanich Molecular mechanisms of microvascular failure in central nervous system injury - synergistic roles of NKCC1 and SUR1/TRPM4 J. Neurosurg. 113 2010 622 629
F. Branle, F. Lefranc, I. Camby, J. Jeuken, A. Geurts-Moespot, S. Sprenger, F. Sweep, R. Kiss, and I. Salmon Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy Cancer 95 2002 641 655 (Pubitemid 34810191)
B. Sivasankaran, M. Degen, A. Ghaffari, M.E. Hegi, M.F. Hamou, M.C.S. Ionescu, C. Zweifel, M. Tolnay, M. Wasner, S. Mergenthaler, A.R. Miserez, R. Kiss, M.M. Lino, A. Merlo, R. Chiquet-Ehrismann, and J.L. Boulay Tenascin-C is a novel RBPJk-induced target gene for notch signaling in gliomas Cancer Res. 69 2009 458 465
N. Belot, R. Pochet, C.W. Heizmann, R. Kiss, and C. Decaestecker Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton Biochim. Biophys. Acta 1600 2002 74 83 (Pubitemid 38224401)
M. Le Mercier, S. Fortin, V. Mathieu, I. Roland, S. Spiegl-Kreinecker, B. Haibe-Kains, G. Bontempi, C. Decaestecker, W. Berger, F. Lefranc, and R. Kiss Galectin-1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression Neoplasia 11 2009 485 496
L. Ingrassia, F. Lefranc, J. Dewelle, L. Pottier, V. Mathieu, S. Spiegl-Kreinecker, S. Sauvage, M. El Yazidi, M. Dehoux, W. Berger, E. Van Quaquebeke, and R. Kiss Structure-activity-relationship analysis of novel derivatives of narciclasine (an amaryllidaceae isocarbostyril alkaloid) as potential anti-cancer agents J. Med. Chem. 52 2009 1100 1114
C. Decaestecker, O. Debeir, P. Van Ham, and R. Kiss Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration (review) Med. Res. Rev. 27 2007 149 176 (Pubitemid 46281145)
C.D. Hurd, and S. Hayao Chromanones, thiochromanones, and 2,3-dihydro-4(1H)-quinolones J. Am. Chem. Soc. 76 1954 5065 5069
G. Canalini, I. Degani, R. Fochi, and G. Spunta Heteroaromatic cations. X. Hydrolysis of some chromylium perchlorate derivatives Ann. Chim. 57 1967 1045 1072
G. Charest, L. Sanche, D. Fortin, D. Mathieu, B. Paquette, Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy, Int. J. Radiat. Oncol. Biol. Biophys. in press.
M. Varasi, F. Thaler, A. Abate, C. Bigogno, R. Boggio, G. Carenzi, T. Cataudella, R. Dal Zuffo, M.C. Fulco, M.G. Rozio, A. Mai, G. Dondio, S. Minucci, and C. Mercurio Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors J. Med. Chem. 54 2011 3051 3064
R.G. Schmidt, E.K. Bayburt, S.P. Latshaw, J.R. Koenig, J.F. Daanen, H.A. McDonald, B.R. Bianchi, C. Zhong, S. Joshi, P. Honore, K.C. Marsh, C.H. Lee, C.R. Faltynek, and A. Gomtsyan Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists Bioorg. Med. Chem. Lett. 21 2011 1338 1341
R. Reilly, H. McDonald, P. Puttfarcken, S. Joshi, L. Lewis, M. Pai, P. Franklin, J. Segreti, T. Neelands, P. Han, J. Chen, P. Mantyh, J. Ghilardi, T. Turner, E. Voight, J. Daanen, R. Schmidt, A. Gomtsyan, M. Kort, C. Faltynek, P. Kym P, Novel TRPV1 receptor antagonists that partially block acid activation: in vitro pharmacology predicts effects on core body temperature and in vivo efficacy, J. Pharmacol. Exp. Ther. in press.
K.M. Mahar Doan, J.E. Humphreys, L.O. Webster, S.A. Wring, L.J. Shampine, C.J. Serabit-Singh, K.K. Adkinson, and J.W. Polli Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs J. Pharmacol. Exp. Ther. 303 2002 1029 1037 (Pubitemid 35424386)
C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25 (Pubitemid 27046991)
H. Pajouhesh, and G.R. Lenz Medicinal chemical properties of successful central nervous system drugs NeuroRx 2 2005 541 553 (Pubitemid 41393264)
I.V. Tetko, J. Gasteiger, R. Todeschini, A. Mauri, D. Livingstone, P. Ertl, V.A. Palyulin, E.V. Radchenko, N.S. Zefirov, A.S. Makarenko, V.Y. Tanchuk, and V.V. Prokopenko Virtual computational chemistry laboratory - design and description J. Comput. Aid. Mol. Des. 19 2005 453 463 (Pubitemid 41613292)
D. Stephan, E. Salamon, H. Weber, U. Russ, H. Lemoine, and U. Quast KATP channel openers of the benzopyran type reach their binding site via the cytosol Br. J. Pharmacol. 149 2006 199 205 (Pubitemid 44360101)
D. Lamoral-Theys, A. Andolfi, G. Van Goietsenoven, A. Cimmino, B. Le Calvé, N. Wauthoz, V. Mégalizzi, T. Gras, C. Bruyère, J. Dubois, V. Mathieu, A. Kornienko, R. Kiss, and A. Evidente Lycorine, the main phenanthridine amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight J. Med. Chem. 52 2009 6244 6256
